U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284758) titled 'A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma' on Dec. 09.
Brief Summary: This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Intervention:
DRUG: Cemsidomide
dosed orally (PO) once a day (QD) 14 days on/14 days of...